PMDA drug package insert
ガバペン錠200mg
PMDA Prescription drug · 富士製薬工業株式会社 · package insert Apr 30, 2026
Key facts
| Brand names | ガバペン錠200mg, ガバペン錠300mg, ガバペン錠400mg |
|---|---|
| Nonproprietary names | ガバペンチン |
| Companies | 製造販売元／富士製薬工業株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 抗てんかん剤 |
| Therapeutic category codes | 871139 |
| YJ codes | 1139007F1022, 1139007F2029, 1139007F3025 |
| Approval numbers | 21800AMZ10365, 21800AMZ10366, 21800AMZ10367 |
| Package insert edition | 第4版 |
| Package insert date | Apr 30, 2026 |
| PMDA document key | 670109_1139007F1022_3 |
| PMDA company code | 670109 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: